A novel AMPK activator improves hepatic lipid metabolism and leukocyte trafficking in experimental hepatic steatosis
A novel AMP-activated protein kinase (AMPK) activator, IMM-H007 (H007), has been reported to reduce serum lipid levels and inhibit lipid accumulation in the liver in hyperlipidemic animal models. However, how H007 ameliorates hepatic steatosis and inflammation remains unknown. In the present study,...
Saved in:
Main Authors: | Xueying Peng (Author), Jin Li (Author), Minjie Wang (Author), Kai Qu (Author), Haibo Zhu (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2019-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biochemical Markers of Lipid Metabolism Disorders in Children with Hepatic Steatosis
by: N.Yu. Zavhorodnia, et al.
Published: (2015) -
Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism
by: Xin Qiao, et al.
Published: (2019) -
AMPK activation caused by reduced liver lactate metabolism protects against hepatic steatosis in MCT1 haploinsufficient mice
by: Lionel Carneiro, et al.
Published: (2017) -
Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway
by: Liuran Li, et al.
Published: (2021) -
Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro
by: Ting Li, et al.
Published: (2021)